Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Abstract
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in...
Paper Details
Title
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Published Date
Jul 7, 2020
Journal
Volume
4
Issue
13
Pages
3085 - 3092
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History